36 search results for: mechanism of disease

Distinct <b>Mechanism</b>s Drive Inflammation and Itch in Chronic, Type 2 Inflammatory <b>Disease</b>s
Type 2 Inflammation
Distinct Mechanisms Drive Inflammation and Itch in Chronic, Type 2 Inflammatory Diseases
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Brian Kim provides an overview of itch in type 2 inflammatory skin diseases and explains how the shared and unique mechanisms that drive inflammation and itch mediate each disease in distinct ways.

View more
Type 2 Inflammatory <b>Disease</b>: What Are the <b>Mechanism</b>s that Contribute to the Development <b>of</b> Other Atopic Comorbidities?
Type 2 Inflammation
Type 2 Inflammatory Disease: What Are the Mechanisms that Contribute to the Development of Other Atopic Comorbidities?
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 inflammation and barrier dysfunction contribute to the development of atopic comorbidities and increased susceptibility to infections.

View more
ADVENT Forum 2025 On Demand page
On Demand
ADVENT Forum 2025 On Demand page

Watch on-demand expert soundbites recorded at the April 2025 ADVENT Forum in Lisbon, Portugal, featuring dermatology and immunology perspectives on mechanisms and clinical practice. Topics range from disease mechanism to patient care and quality of life, spanning atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
On Demand
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

2025 ADVENT Forum | Remodeling in the Airway: A Damaged State <b>of</b> Affairs
Type 2 Inflammation
2025 ADVENT Forum | Remodeling in the Airway: A Damaged State of Affairs
expert video

Explore the intricate world of airway remodeling with this comprehensive recording of the live session held at the 2025 ADVENT Forum: "Remodeling in the Airway: A Damaged State of Affairs." Moderated by Dr. Stella Lee, this session brings together a powerhouse multidisciplinary panel to dissect the multifaceted nature of airway damage.

View more
CEORL-HNS 2026 | Emerging Evidence <b>of</b> Biologics for the Treatment Landscape <b>of</b> CRSwNP
Rhinology
CEORL-HNS 2026 | Emerging Evidence of Biologics for the Treatment Landscape of CRSwNP
expert video

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

View more
ADVENT at ATS 2026
On Demand
ADVENT at ATS 2026

At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.​

The Benefits <b>of</b> Early Intervention in Reducing the Burden <b>of</b> <b>Disease</b> in Children With Atopic Dermatitis
On Demand
The Benefits of Early Intervention in Reducing the Burden of Disease in Children With Atopic Dermatitis

This page presents educational material, infographics, and video highlights from our recent ADVENT symposia, including the 2025 World Congress of Pediatric Dermatology (WCPD) in Buenos Aires, Argentina, exploring the pathophysiology of type 2 inflammation and atopic dermatitis, the burden of disease leading to cumulative life course impairment (CLCI), and the risk of the atopic march in pediatric patients with atopic dermatitis.

Event Page Thumbnail
Congress
27
April
2026
Congress
ADVENT at CEORL-HNS 2026

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

thumbnail
Congress
17
May
2026
Congress
ADVENT at ATS 2026

At ATS 2026, the Sanofi & Regeneron ADVENT Booth #1301 brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.​

Coexisting Type 2 Inflammatory <b>Disease</b>s Can Add to the Patient Overall <b>Disease</b> Burden
Type 2 Inflammation
Coexisting Type 2 Inflammatory Diseases Can Add to the Patient Overall Disease Burden
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares highlights how patients with type 2 inflammatory diseases often experience multimorbidities, with overlapping symptoms that amplify their overall disease burden and impact quality of life.

View more
Which Biomarkers <b>of</b> AD Might Be Robust Enough to Be Evaluated as a Measure <b>of</b> <b>Disease</b> Modification?
Dermatology
Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares reviews the cellular and molecular pathways underlying atopic dermatitis and considers which biomarkers may one day serve as robust measures of disease modification, despite no validated options currently being available.

View more